Expand EXEL Menu
EXEL MENU

EXEL Latest Press Releases

-- May 21, 2026 --

Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types Business Wire 5:00 PM

-- May 19, 2026 --

Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer Business Wire 8:00 AM

-- May 7, 2026 --

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May Business Wire 4:05 PM

-- May 5, 2026 --

Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update Business Wire 4:05 PM

-- April 21, 2026 --

Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026 Business Wire 4:05 PM

-- February 24, 2026 --

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March Business Wire 4:05 PM

-- February 10, 2026 --

Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update Business Wire 4:05 PM

-- February 2, 2026 --

Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer Business Wire 8:00 AM

-- January 27, 2026 --

Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026 Business Wire 4:05 PM

-- January 11, 2026 --

Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 Business Wire 4:00 PM

-- January 7, 2026 --

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer Business Wire 8:00 AM

-- January 6, 2026 --

Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026 Business Wire 4:05 PM
Market Data Delayed 15 Minutes